[go: up one dir, main page]

NO20000855L - Radioaktive liposomer til terapi - Google Patents

Radioaktive liposomer til terapi

Info

Publication number
NO20000855L
NO20000855L NO20000855A NO20000855A NO20000855L NO 20000855 L NO20000855 L NO 20000855L NO 20000855 A NO20000855 A NO 20000855A NO 20000855 A NO20000855 A NO 20000855A NO 20000855 L NO20000855 L NO 20000855L
Authority
NO
Norway
Prior art keywords
liposomes
therapy
radioactive
radioactive liposomes
ionophores
Prior art date
Application number
NO20000855A
Other languages
English (en)
Other versions
NO312708B1 (no
NO20000855D0 (no
Inventor
Roy H Larsen
Gjermund Henriksen
Original Assignee
Anticancer Therapeutic Inv Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer Therapeutic Inv Sa filed Critical Anticancer Therapeutic Inv Sa
Priority to NO20000855A priority Critical patent/NO312708B1/no
Publication of NO20000855D0 publication Critical patent/NO20000855D0/no
Priority to DK01910251T priority patent/DK1257299T3/da
Priority to AU3782701A priority patent/AU3782701A/xx
Priority to MXPA02008110A priority patent/MXPA02008110A/es
Priority to KR1020027010848A priority patent/KR100822566B1/ko
Priority to PCT/NO2001/000065 priority patent/WO2001060417A2/en
Priority to US09/790,260 priority patent/US6592843B2/en
Priority to CNB018053726A priority patent/CN100350981C/zh
Priority to ES01910251T priority patent/ES2247069T3/es
Priority to NZ520848A priority patent/NZ520848A/en
Priority to JP2001559512A priority patent/JP4933712B2/ja
Priority to BR0108572-7A priority patent/BR0108572A/pt
Priority to AT01910251T priority patent/ATE300316T1/de
Priority to CZ20023164A priority patent/CZ299032B6/cs
Priority to CA002400994A priority patent/CA2400994C/en
Priority to PL358541A priority patent/PL201398B1/pl
Priority to AU2001237827A priority patent/AU2001237827B2/en
Priority to DE60112251T priority patent/DE60112251T2/de
Priority to UA2002086850A priority patent/UA73160C2/uk
Priority to EP01910251A priority patent/EP1257299B9/en
Priority to EA200200793A priority patent/EA005624B1/ru
Publication of NO20000855L publication Critical patent/NO20000855L/no
Publication of NO312708B1 publication Critical patent/NO312708B1/no
Priority to ZA200206500A priority patent/ZA200206500B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20000855A 2000-02-21 2000-02-21 Radioaktive liposomer til terapi NO312708B1 (no)

Priority Applications (22)

Application Number Priority Date Filing Date Title
NO20000855A NO312708B1 (no) 2000-02-21 2000-02-21 Radioaktive liposomer til terapi
EA200200793A EA005624B1 (ru) 2000-02-21 2001-02-21 Радиоактивные терапевтические липосомы
JP2001559512A JP4933712B2 (ja) 2000-02-21 2001-02-21 放射線治療用リポソーム
AT01910251T ATE300316T1 (de) 2000-02-21 2001-02-21 Radioaktive therapeutische liposomen
MXPA02008110A MXPA02008110A (es) 2000-02-21 2001-02-21 Liposomas terapeuticos radioactivos.
KR1020027010848A KR100822566B1 (ko) 2000-02-21 2001-02-21 방사성 치료 리포좀
PCT/NO2001/000065 WO2001060417A2 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
US09/790,260 US6592843B2 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
CNB018053726A CN100350981C (zh) 2000-02-21 2001-02-21 有放射活性的治疗性脂质体
ES01910251T ES2247069T3 (es) 2000-02-21 2001-02-21 Liposomas terapeuticos radioactivos.
NZ520848A NZ520848A (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
DK01910251T DK1257299T3 (da) 2000-02-21 2001-02-21 Radioaktive, terapeutiske liposomer
BR0108572-7A BR0108572A (pt) 2000-02-21 2001-02-21 Sistema conjugador, método para preparar um sistema conjugador radiorrotulado, uso do sistema conjugador, método para utilizar o sistema conjugador, e, kit para a preparação do sistema conjugador
AU3782701A AU3782701A (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
CZ20023164A CZ299032B6 (cs) 2000-02-21 2001-02-21 Konjugátorový systém
CA002400994A CA2400994C (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
PL358541A PL201398B1 (pl) 2000-02-21 2001-02-21 System koniugatora radionuklid-liposom, sposób jego wytwarzania, zastosowanie systemu koniugatora do wytwarzania roztworu farmaceutycznego, zastosowanie terapeutyczne systemu koniugatora oraz zestaw do wytwarzania systemu koniugatora
AU2001237827A AU2001237827B2 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
DE60112251T DE60112251T2 (de) 2000-02-21 2001-02-21 Radioaktive therapeutische liposomen
UA2002086850A UA73160C2 (uk) 2000-02-21 2001-02-21 Кон'югаційна система, що являє собою радіоактивні терапевтичні ліпосоми, спосіб їх одержання та застосування
EP01910251A EP1257299B9 (en) 2000-02-21 2001-02-21 Radioactive therapeutic liposomes
ZA200206500A ZA200206500B (en) 2000-02-21 2002-08-14 Radioactive therapeutic liposomes.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20000855A NO312708B1 (no) 2000-02-21 2000-02-21 Radioaktive liposomer til terapi

Publications (3)

Publication Number Publication Date
NO20000855D0 NO20000855D0 (no) 2000-02-21
NO20000855L true NO20000855L (no) 2001-08-22
NO312708B1 NO312708B1 (no) 2002-06-24

Family

ID=19910768

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000855A NO312708B1 (no) 2000-02-21 2000-02-21 Radioaktive liposomer til terapi

Country Status (21)

Country Link
US (1) US6592843B2 (no)
EP (1) EP1257299B9 (no)
JP (1) JP4933712B2 (no)
KR (1) KR100822566B1 (no)
CN (1) CN100350981C (no)
AT (1) ATE300316T1 (no)
AU (2) AU2001237827B2 (no)
BR (1) BR0108572A (no)
CA (1) CA2400994C (no)
CZ (1) CZ299032B6 (no)
DE (1) DE60112251T2 (no)
DK (1) DK1257299T3 (no)
EA (1) EA005624B1 (no)
ES (1) ES2247069T3 (no)
MX (1) MXPA02008110A (no)
NO (1) NO312708B1 (no)
NZ (1) NZ520848A (no)
PL (1) PL201398B1 (no)
UA (1) UA73160C2 (no)
WO (1) WO2001060417A2 (no)
ZA (1) ZA200206500B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
US8029795B2 (en) * 1999-12-30 2011-10-04 Gwathmey, Inc. Targeted iron chelator delivery system
CA2411826A1 (en) * 2000-06-16 2001-12-27 Sloan-Kettering Institute For Cancer Research Liposomal encapsulation of chelated actinium-225 and uses thereof
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
KR101274867B1 (ko) * 2003-04-15 2013-06-13 알게타 에이에스 연조직 질환의 방사선 치료에 사용하기 위한 토륨-227
CN102293746A (zh) * 2003-09-09 2011-12-28 吉里德科学公司 治疗性脂质体
EP1735013B1 (en) * 2004-02-20 2012-02-08 Algeta ASA Alpha- and beta-emitting hydroxyapatite particles
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
US20070065359A1 (en) * 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
US20070224115A1 (en) * 2006-03-22 2007-09-27 The Regents Of The University Of California Polymeric chelators for radionuclide delivery systems
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
US20100178244A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
US8920775B2 (en) 2009-07-17 2014-12-30 Technical University Of Denmark Loading technique for preparing radionuclide containing nanoparticles
JP2011111438A (ja) * 2009-11-30 2011-06-09 Akita Univ 有機金属錯体を有効成分として含有する抗がん剤
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
US9226984B2 (en) 2010-12-14 2016-01-05 Technical University of Denmark and Rigshospitalet Entrapment of radionuclides in nanoparticle compositions
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
DE102011079031A1 (de) * 2011-07-12 2013-01-17 Algeta Asa Flüssigkeitsbehälter
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
WO2014164712A1 (en) 2013-03-11 2014-10-09 Wayne State University Formation and uses of europium
ES2657388T3 (es) * 2015-02-26 2018-03-05 Sciencons AS Disoluciones radiofarmacéuticas con propiedades ventajosas
DK3261681T3 (da) * 2015-02-26 2020-04-27 Sciencons AS Radiofarmaceutiske opløsninger med fordelagtige egenskaber
US9433690B1 (en) * 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
SI3111959T1 (en) * 2015-07-03 2018-04-30 Oncoinvent As Radiotherapeutic particles and suspensions
CN108778347A (zh) 2016-03-24 2018-11-09 拜耳制药股份公司 放射性药物配合物
WO2017211809A1 (en) 2016-06-10 2017-12-14 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
CA3026599A1 (en) * 2016-06-24 2017-12-28 Sciencons AS Preparation of 212pb labeled monoclonal antibodies
CN110603076A (zh) 2017-05-11 2019-12-20 阿尔法陶医疗有限公司 用于近距离放射治疗装置的聚合物涂层
RU2020130217A (ru) 2018-04-02 2022-05-04 Альфа Тау Медикал Лтд. Контролируемое высвобождение радионуклидов
EP4003959A1 (en) 2019-07-25 2022-06-01 Bayer AS Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
MX2022006638A (es) 2019-12-05 2022-07-19 Sciencons AS Producción de 212pb altamente purificados.
AU2021400142B2 (en) 2020-12-16 2024-11-21 Alpha Tau Medical Ltd. Diffusing alpha-emitters radiation therapy with enhanced beta treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
DK482685D0 (da) * 1984-10-22 1985-10-21 Hope Nat Medical Center Fremgangsmaade til tilfoersel af micellulaere partikler, der indkapslerbilleddannende og kemoterapeutiske midler, til tumorer i et legeme
CA1314209C (en) * 1987-11-04 1993-03-09 Gary Fujii Composition and method for use for liposome encapsulated compounds for neutron capture tumor therapy
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
DE69331319T2 (de) * 1992-06-09 2002-08-08 Neorx Corp., Seattle Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
ES2299256T3 (es) * 1998-05-26 2008-05-16 Sloan-Kettering Institute For Cancer Research Constructos que emiten particulas alfa y sus usos.

Also Published As

Publication number Publication date
AU2001237827B8 (en) 2001-08-27
WO2001060417A2 (en) 2001-08-23
EP1257299B1 (en) 2005-07-27
JP4933712B2 (ja) 2012-05-16
CZ20023164A3 (cs) 2003-04-16
US20010048914A1 (en) 2001-12-06
ES2247069T3 (es) 2006-03-01
CN1404402A (zh) 2003-03-19
KR20020092963A (ko) 2002-12-12
WO2001060417A3 (en) 2002-02-07
ZA200206500B (en) 2003-08-14
EA200200793A1 (ru) 2003-02-27
CZ299032B6 (cs) 2008-04-09
JP2003522808A (ja) 2003-07-29
PL358541A1 (en) 2004-08-09
ATE300316T1 (de) 2005-08-15
EA005624B1 (ru) 2005-04-28
CA2400994A1 (en) 2001-08-23
DK1257299T3 (da) 2005-11-21
EP1257299A2 (en) 2002-11-20
KR100822566B1 (ko) 2008-04-16
NO312708B1 (no) 2002-06-24
US6592843B2 (en) 2003-07-15
PL201398B1 (pl) 2009-04-30
EP1257299B9 (en) 2005-11-30
BR0108572A (pt) 2002-11-19
CA2400994C (en) 2009-07-07
UA73160C2 (uk) 2005-06-15
NO20000855D0 (no) 2000-02-21
NZ520848A (en) 2005-02-25
DE60112251T2 (de) 2006-03-30
MXPA02008110A (es) 2003-12-11
DE60112251D1 (de) 2005-09-01
AU2001237827B2 (en) 2007-11-22
CN100350981C (zh) 2007-11-28
AU3782701A (en) 2001-08-27

Similar Documents

Publication Publication Date Title
NO20000855D0 (no) Radioaktive liposomer til terapi
TR200100623T2 (tr) 5-Tia-w-ikameli fenil-prostaglandin türevleri, bunları üretme yöntemleri ve müessir madde olarak bunları ihtiva eden ilaçlar
GB0105772D0 (en) Use
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
MXPA04009163A (es) Nuevos compuestos.
GT199900019A (es) Formulas farmaceuticamente estables de solucion de oxaliplatino.
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE367816T1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
HUP0104973A2 (hu) Különböző kinázokra és ciklin/CDK-komplexokra inhibitor hatású új, szubsztituált indolinonok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
AP2001002274A0 (en) Rescorcinol derivatives.
MY137580A (en) Radioactive therapeutic liposomes
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
GB2342352B (en) Pure cis-tramadol hydrochloride production
ATE328899T1 (de) Zellkernlokalisierendes protein für beta-catenin
AP2002002547A0 (en) Calcilytic compounds.
ATE343390T1 (de) Kalzilytische verbindungen
IS6017A (is) Aðferð til meðhöndlunar á höfuðverk
BR0207953A (pt) Derivados de caloporosida, processos para a sua preparação e sua aplicação
UA33493A (uk) Розчин для кислотної обробки свердловин
ES545563A0 (es) Procedimiento para producir clorhidrato de l-norcarnitina
ECSP003635A (es) Formas de admnistracion de tramadol retardadas, mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asi como eventualmente otros excipientes
UA37377A (uk) Спосіб отримання мазі для лікування захворювань, які викликані внутрішньоклітинними інфекційними агентами

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees